Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects

Booking.com

Stockholm, June 12 2019: A new paper in the Journal of Neuroendocrinology shows how Asarina Pharma’s compound Sepranolone reduced tics in an animal model of Tourette syndrome as effectively as current first-line treatment Haldol—without inducing any motor side effects.
The paper, Isoallopregnanolone reduces tic-like behaviors in the D1CT-7 mouse model of Tourette syndrome is co-authored by, amongst others, Marco Bortolato, Prof of Pharmacology and Toxicology at the University of Utah, and Torbjörn Bäckström, Senior Professor in Obstetrics and Gynecology at the University of Umeå and CSO of

Source: Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.